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Abstract. In humans, homocysteine (Hcy) is employed to monitor renal, cardiovascular, and other
diseases and their complications. The aim of the current study was to define the analytical performances of an
enzymatic method not yet validated in dogs for measuring homocysteine, and to assess the possible clinical
usefulness of Hcy measurement. Using conventional approaches, the analytical performances were
investigated by assessing, imprecision, inaccuracy, and interference of hemoglobin, triglycerides, and
bilirubin. The possible clinical usefulness of Hcy determination was assessed by comparing the results of
healthy dogs (n 5 8) with those of dogs with heart disease (n 5 10), inflammation (n 5 6), gastrointestinal
disorders (n 5 7), neoplasia (n 5 8), renal failure (n 5 4), trauma (n 5 7), and other miscellaneous diseases (n
5 6). Preliminary evaluation of this enzymatic method showed it to be precise at Hcy levels close to or higher
than the values in dogs with renal or cardiac disorders that had the highest Hcy levels. By contrast, at low Hcy
levels, which were recorded basically in control dogs, the method suffers from high imprecision. The sample of
choice is serum. The use of icteric samples should be avoided, while hemoglobin and lipids have only a minor
effect on Hcy measurement. In conclusion, the enzymatic method employed in the current study provides
useful information in dogs and could be used to monitor cardiac and renal disorders, in which Hcy
concentrations are elevated.
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Homocysteine (Hcy) is a sulfur-containing intermediate
product of methionine metabolism and is further metabo-
lized by vitamin B12- or B6-dependent pathways.
17 In
humans, hyperhomocysteinemia (HHcy) is a sensitive
marker of folate and B-vitamin deficiency and is considered
an independent risk factor for cardiovascular disease
(CVD) and thrombotic-, neurodegenerative-, and D-
pregnancy-associated diseases.13,17 Specifically, HHcy is
associated with an increased incidence of congestive heart
failure (CHF), as well as with the severity of the disease. In
high-risk populations, increased Hcy is a prognostic marker
for an increased risk of new CVD events or mortality.7
High plasma concentrations of Hcy and low levels of B
vitamins are risk factors for coronary and cerebral
atherosclerosis and peripheral vascular disease.4 Moreover,
HHcy has been shown to be an independent risk factor for
cardiovascular disease in renal patients5,12,16; plasmatic
levels of Hcy are inversely correlated with the glomerular
filtration rate (GFR)5 and positively correlated with serum
creatinine.16 Further, an increased risk of mortality was
found in patients with HHcy and diabetes.18
In the veterinary literature, publications on the possible
usefulness of Hcy as a risk factor or as a prognostic or
diagnostic biomarker are rare. Studies in cats with heart
diseases or arterial thromboembolism (ATE) provided
controversial results (Hohenhaus AE, Simantov R, Fox
PR, et al.: 1999, Evaluation of plasma homocysteine and B
vitamin concentrations in cardiomyopathic cats with
congestive heart failure and arterial thromboembolism.
In: Proceedings of the Nestle Purina Nutrition Forum,
p. 170. St. Louis, MO),11 and studies on the relationship
between Hcy concentration in cats and hypocobalaminemia
or cobalamin therapy suggested that serum Hcy concen-
tration does not depend upon cobalamin availability.14,15
The only study for dogs2 demonstrated that Hcy levels were
not affected by the short-term administration of a
peripheral parenteral nutrition product. All the studies
published in veterinary medicine employed high-perfor-
mance liquid chromatography (HPLC), which is accurate
but unpractical, expensive, and requires long run-times and
specialized personnel. The aims of the current study were to
investigate the analytical performances of an enzymatic
colorimetric method for measurement of Hcy on canine
samples that had previously been validated with human
samples3 and to assess Hcy levels in healthy dogs and in
dogs affected by different pathologic conditions to deter-
mine the possible clinical usefulness of this parameter.
Fifty-six canine blood samples were obtained, under
informed consent, from client-owned dogs referred to the
authors’ respective institutions for various diagnostic or
therapeutic measures. The samples were put in plastic tubes
containing clot activator and separation gel.a Sera were
obtained by centrifugation (1500 3 g for 7 min) within
30 min, and subsequently stored in plastic tubes at 220uC
until analysis, for no longer than 1 month. To assess the
possible influence of anticoagulants in 8 cases, aliquots of
blood were also put into ethylenediamine tetra-acetic acid
(EDTA) plastic tubesb and lithium-heparin plastic tubesb
filled to their maximum capacity. Sera or plasma samples
from the dogs were collected within 30 min by centrifuga-
tion at 1500 3 g for 15 min and immediately analyzed.
Based on clinical examination, hematology, clinical
biochemistry, and additional diagnostic tests, such as
radiography and ultrasonography, dogs were classified in
the following groups:
N Control: 8 dogs (3 males, 5 females; age range: 1–
6 years; median age: 2.5 years) sampled during
routine wellness visits or before spaying/neutering.
When sampled, these dogs did not show any clinical
or laboratory abnormalities, especially regarding
heart and kidney functions.
N Heart disease: 10 dogs (6 males, 4 females; age range:
1–14 years; median age: 8 years). This group included
dogs with dilated cardiomyopathy, mitral insufficien-
cy, pulmonic stenosis, congenital arrhythmia, and
patent ductus arteriosus.
N Inflammation: 6 dogs (1 male, 5 females; age range: 3–
11 years; median age: 5.5 years) with pyometra (n 5
2), eosinophilic pneumonia, ehrlichiosis, leishmania-
sis, or pyoderma.
N Gastrointestinal disorders: 7 dogs (3 males, 4 females;
age range: 3–12 years; median age: 8 years) with
pyloric stenosis (n 5 3), intestinal obstruction (n 5 3),
or gastric ulceration (n 5 1).
N Neoplasia: 8 dogs (4 males, 4 females; age range: 7–
12 years; median age: 10 years). Neoplasms diag-
nosed in these dogs included histiocytoma, pulmonary
carcinoma, lipoma, mammary carcinoma, ovarian
carcinoma, and synoviosarcoma. Insulinoma was
suspected in 1 case. In another case, a splenic mass
was identified but not further investigated by cytology
or histology.
N Kidney disease: 4 dogs (1 male, 3 females; age range:
10–17 years; median age: 11 years). All dogs in this
group had increased creatinine and urea with
additional biochemical changes consistent with renal
azotemia caused by chronic renal failure (n 5 3) or
acute renal failure (n 5 1).
N Trauma: 7 dogs (1 male, 6 female; age range: 1–
10 years; median age: 3 years) that experienced
traumatic events, including fractures or joint injuries.
N Miscellaneous diseases: 6 dogs (3 males, 3 females; age
range: 1–11 years; median age: 6.8 years). This group
included dogs with gastric torsion, postsurgical
hemorrhage, chronic diaphragmatic hernia, and
neurological signs of undetermined origin (n 5 2).
Homocysteine was measured with an automated spectro-
photometerc using a commercially available kit based on an
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enzymatic cycling reaction that detects Hcy in human
serum or plasma.d,3 At the beginning of each batch of tests,
the instrument was calibrated using the human-based
calibrator provided by the manufacturer of the kit,d and
human-based control solutionsd (low control 5 7.0 6
1.1 mmol/l; high control 5 29.0 6 4.4 mmol/l) were
employed to assess the efficiency of the calibration.
After thawing, Hcy concentration was determined for all
serum samples by measuring each sample in triplicate. The
mean value, the standard deviation (SD), and the
coefficient of variation (CV 5 SD/mean 3 100) were
calculated using an Excele spreadsheet with Analyse-it
software.f The same software was used to perform all the
statistical analyses.
Samples were then used to prepare the reference material
listed in Table 1. Except for the ‘‘high Hcy level’’ sample
(sample A), which was prepared by aliquoting the sample
with the highest Hcy concentration, all the reference
samples were obtained by pooling sera with medium-to-
high (pools B and D) or medium-to-low (pools C, E, and F)
concentrations of Hcy. Aliquots of each pool were assayed
immediately or, as regards interassay variability, stored
frozen at 220uC. The analytical characteristics of the tests
on canine samples were assessed by a basic panel of
validation procedures suggested in the published litera-
ture19 and previously employed in similar studies.8 Al-
though less complete than other validation approaches
(based on additional tests and on higher numbers of
replicates), this basic panel was considered adequate to
provide preliminary information on analytical aspects and
on the possible clinical usefulness of Hcy concentration in
the blood.9,19
The intra-assay variability was determined by measuring
the Hcy concentration of sample A, and of pools B and C,
20 consecutive times in a single run. The CVs, calculated as
reported above, were 11.7%, 9.0%, and 4.1%, respectively.
The interassay variability was assessed by analyzing
samples A, B, and C in triplicate on 5 successive days.
The CVs, calculated by measuring the pooled variance
estimate,8 were 10.6%, 7.0%, and 2.8%, respectively. The
lower limit of detection (LLOD) was calculated from 10
replicate measurements of saline solution (0.9% NaCl),
which always provided undetectable results. The results
suggest that the analytical method is precise and has a very
low LLOD, but the results of the interassay imprecision test
were probably biased by the low number of runs. This bias
was confirmed by data from individual dogs; the majority
(15/18) of samples with less than 5.0 mmol/l had CVs
.20%, whereas only 2 of the remaining 38 samples, which
had .5.0 mmol/l, had CVs higher than 20% (considered the
maximum allowable imprecision for many biochemical
tests).19
Although the lower limit of quantification (the lowest
amount of the analyte that can be determined with suitable
precision and accuracy) has not been statistically assessed in
the current study, the poor precision at low Hcy levels was
confirmed by the results of the linearity under dilution
(LUD) test and the recovery tests. Although these 2 tests
cannot replace conventional approaches to evaluate the
inaccuracy of tests (e.g., method comparison and proficiency
testing, which are not available for the Hcy method employed
in this study),9 in many papers,8,10 LUD and recovery tests
are used as indirect methods to ‘‘estimate’’ inaccuracy and to
provide information about reportable ranges and propor-
tional systematic errors, respectively.9,19 The LUD test was
performed by diluting pool D with saline solution to obtain
samples containing 80%, 60%, 40%, and 20% of the analyte.
The recovery test was performed by adding 3 aliquots (100 ml
each) of pool E to 3 different volumes (25, 50, and 75 ml) of
pool D. All the samples, including undiluted pools D and E,
were analyzed in triplicate. The percentage of recovery
compared with expected values (Table 2) was close to 100%
for both the tests except for the sample corresponding to 20%
dilution. Least square linear regression (Fig. 1) demonstrated
an excellent degree of correlation for both LUD (R25 0.99; P
5 0.000) and recovery (R2 5 0.98; P 5 0.011) tests. In both
cases, data fit the linear model. The results demonstrate that
the analytical method was linear in the range of values
examined and that no proportional systematic errors were
present.
The effect of hemolysis and hyperlipemia was assessed
using previously published protocols.10 Aliquots of pooled
sera were added with different concentrations of hemoglo-
bin (Hb)g or commercial fat emulsion (Trig)h to pool F, or
of bilirubin (Bil)i to pool G, followed by triplicate
measurement of Hcy. The following levels of hemolysis,
lipemia, and icterus were simulated: slight (Hb ,1.25 g/l;
Trig ,2.1 g/l; Bil 5 0.0275 g/l), moderate (Hb 5 2.5 g/l;
Trigl 5 3.6 g/l; Bil 5 0.045 g/l), severe (Hb 5 5.0 g/l; Trigl
5 6.1 g/l; Bil 5 0.08 g/l), and extreme (Hb 5 7.5 g/l; Trigl
5 8.6 g/l; Bil 5 0.15 g/l). The final concentrations of Hb
were verified by an hematology analyzer,j those of Trig by
the enzymatic colorimetric glycerol-3-phosphate-oxidase–
peroxidase (GPO-POD) method,k and those of Bil by the
modified Jendrassik-Grof method.j The percentage changes
of Hcy concentration compared with the basal sample
(serum + distilled water), on which the concentrations of
Hb, Trig, and Bil were 0 g/l, 1.1 g/l, and 0.01 g/l,
respectively, were calculated and plotted versus the
concentration of interfering substances to create the
interferograms (Fig. 2).10 Moreover, results obtained from
serum with and without the different concentrations of
interfering substances were compared using the Friedman
Table 1. Reference material used to validate the enzymatic




Mean Hcy level of
triplicate measurement
(mmol/l) Test method employed
A 1 32.07 Imprecision test
B 2 14.10 Imprecision test
C 10 6.07 Imprecision test
D 2 23.97 Linearity under dilution
and recovery test
E 2 12.16 Recovery test
F 3 10.26 Interference (hemaglobin,
lipemia)
G 4 11.85 Interference (bilirubin)
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test. The mean values observed in the presence of Hb and
Trig fluctuated around the 100% value of the basal sample,
without statistically significant differences. This suggests
that Hb and Trig had only a limited effect on Hcy
measurement, although in samples simulating severe or
extreme hemolysis and lipemia the imprecision of the test
increased, thus masking the possible statistical significance
of the differences recorded in mean values. Regardless,
these fluctuations were generally within a 10% variation
from the expected value, as also occurs with human
samples.3 In contrast, Bil induced a significant increase of
Hcy (P , 0.001) at a concentration corresponding to
moderate icterus (0.045 g/liter). Although this could be a
statistical artifact due to the low number of replicates, the
deviation from the expected value was very high (32%),
contrary to what has been reported in humans.3 This
suggests that measurement of Hcy in icteric samples can
provide falsely elevated results. It would thus be inadvisable
to measure Hcy in grossly icteric canine samples.
Results obtained in serum, and in EDTA or lithium-
heparin plasma, were compared using the Friedman test.
The mean values obtained were 6.4 6 4.1 mmol/l in serum,
4.7 6 4.0 mmol/l in EDTA plasma (P , 0.001 vs. serum),
and 4.2 6 3.2 mmol/l in lithium-heparin plasma (P , 0.001
vs. serum). The reason why this decrease occurred cannot
be hypothesized by the data presented in the current study.
In humans, delayed centrifugation has been demonstrated
to lead to increased Hcy values because of the release of
Hcy from erythrocytes.1 It is unlikely that this occurred in
the present study because serum and plasma were
centrifuged within 30 min. Also, a possible dilutional effect
of the anticoagulant is unlikely because the decrease of Hcy
in plasma was greater than the percentage of dilution of
blood into the anticoagulant. Despite the reason for this
decrease, serum should be considered the sample of choice
for Hcy testing based on the imprecision of the method at
low Hcy concentrations. This latter point was confirmed by
data from samples with ,2.0 mmol/l of Hcy in serum that
had undetectable levels of Hcy in at least one of the
triplicate measurements of plasma. Again, this decrease
would become less relevant in samples with high Hcy levels.
Nevertheless, reference intervals for serum should be
different from those designed for plasma.
Although the definition of the precise diagnostic or
prognostic role of Hcy measurement in different pathologic













LUD test 23.97 3 23.97 100.0 0.91 3.8
19.17 3 19.83 103.4 2.52 12.7
14.38 3 13.67 95.0 0.78 5.7
9.59 3 10.00 104.3 0.70 7.0
4.79 3 3.67 76.5 1.29 35.1
Recovery test 12.17 3 12.17 100.0 2.24 18.4
14.13 3 13.87 98.1 2.59 18.7
15.54 3 15.63 100.6 1.42 9.1
16.60 3 17.43 105.0 1.27 7.3
Figure 1. Linearity under dilution (LUD) of serum pool D
and recovery tests obtained by mixing different amount of pool E
with a fixed amount of pool D. Observed values (in mmol/l) were
statistically correlated to the expected value according to a linear
model, as demonstrated by the ‘‘lack of fit’’ test. LUD test—
intercept: 20.90 (95% confidence interval [CI]: 23.37 to 1.57);
slope: 1.05 (95% CI: 0.90–1.21); recovery test—intercept: 22.31
(95% CI: 210.27 to 5.64); slope: 1.17 (95% CI: 0.63–1.71).
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conditions, establishment of reference intervals and dis-
crimination values, and the possible influence of variables
such as sex and age on Hcy concentration were out of the
scope of the current study, the potential role of Hcy as a
biomarker in dogs was investigated by comparing partic-
ular categories of diseases. Data from the different groups
of dogs were compared by the Kruskal-Wallis test, followed
by the Dunn’s multiple comparison test, to investigate
possible group differences. Control dogs had a mean Hcy
value of 5.72 6 3.26 mmol/l (median 5 5.82 mmol/l, min.–
max. range: 1.43–11.23 mmol/l). This value demonstrated
that test results .5.0 mmol/l are likely to be clinically
relevant. It is thus unlikely that the imprecision of the
method at low Hcy levels would affect clinical decisions.
The other groups had Hcy values that were not significantly
different from those of the control group, with the
exception of dogs with renal diseases (18.86 6
10.15 mmol/l; median: 16.99 mmol/l, min.–max. range:
9.38–32.07 mmol/liter) or with heart disease (10.21 6
6.09 mmol/l; median: 7.64 mmol/l, min.–max. range: 4.47–
24.50 mmol/l), which were significantly different (P , 0.001
and P , 0.05, respectively) from those of the control group
(Fig. 3). The groups included in the present study were
heterogeneous in terms of age, sex, type of pathophysiol-
ogy, and severity of diseases. In addition, there was no
Figure 2. Interferogram for hemoglobin, triglycerides, and
bilirubin. Results are expressed as percentage of the original value.
Each data point represents the mean 6 standard deviation of
triplicate measurement, expressed as percentage variation com-
pared with the basal value. * 5 significantly higher (P , 0.001)
than the baseline value.
Figure 3. Concentration of homocysteine (Hcy) recorded in
the following groups of dogs: C 5 controls; H 5 heart diseases; I
5 inflammation; GI 5 gastrointestinal diseases; N 5 neoplasia; K
5 kidney disease; T 5 trauma; and O 5 others (miscellaneous).
Boxes 5 I–III inter-quartile range; horizontal lines 5 median
value; vertical lines 5 min.–max. range; * 5 P , 0.05 vs. control
group; *** 5 P , 0.001 vs. control group.
Figure 4. Receiver operating characteristic curve showing
the discriminating power of homocysteine for cardiac or renal
diseases.
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information about the presence of complications that were
potentially responsible for hypertension such as arterial
stenosis or endothelial damage. Although statistically
significant sex- or age-related differences were not detected,
it is possible that the other factors mentioned above could
influence the distribution of Hcy values in healthy and
diseased dogs. Nevertheless, the results suggest that, as in
humans, renal and cardiac diseases in dogs are character-
ized by increased Hcy levels. To assess the possible clinical
usefulness of Hcy measurement, for each point value, the
diagnostic specificity and sensitivity of high Hcy concen-
trations were calculated using standard formulae to identify
a ‘‘positive’’ group composed of dogs with renal or cardiac
diseases.19 The discriminating power of Hcy for these
conditions was assessed by designing a receiver operating
characteristic (ROC) curve and by calculating the positive
likelihood ratio.6 The area under the ROC curve (Fig. 4)
was 77%, and the likelihood ratio to distinguish these
conditions from other diseases was .3 at Hcy values
.9.1 mmol/l (data not shown). This information, coupled
with the pretest probability of disease raised by other
clinical, clinicopathological, or instrumental data, could
improve diagnosticians’ ability to detect and monitor renal
and cardiac diseases.
In conclusion, preliminary evaluation demonstrated
that the enzymatic measurement of Hcy on canine samples
was precise at Hcy concentrations close to or higher than
the clinical decision limit. Also, serum should be preferred
to plasma samples, and the use of grossly icteric samples
should be avoided. Additional studies to better define a
possible relationship between Hcy levels and the type of
heart or kidney dysfunction, or between Hcy levels and
other negative prognostic factors, are currently being
investigated at the authors’ respective institutions. To
date, the present study confirms that the enzymatic
method employed in humans to measure Hcy can provide
useful information in dogs and that this biomarker could
play an important role in monitoring renal and cardiac
diseases.
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